Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL297465 | 1.00 | CA5A (0.33) | CA5ACA5BGRM4KDM4EBLM | |
| Vinylsulfonic Acid SCHEMBL4638994 | 0.84 | — | — | |
| SCHEMBL9514804 | 0.82 | — | — | |
| SCHEMBL4559131 | 0.82 | TSHR (0.33) | TSHR | |
| SCHEMBL26368 | 0.82 | — | — | |
| Methylamine SCHEMBL6868266 | 0.78 | TSHR (0.31) | TSHR | |
| Tert-Butylamine SCHEMBL1907227 | 0.78 | TSHR (0.31) | TSHR | |
| Hydrochloric Acid SCHEMBL2860424 | 0.78 | TSHR (0.31) | TSHR | |
| Iodide SCHEMBL5273257 | 0.78 | TSHR (0.31) | TSHR | |
| Deanol SCHEMBL9445594 | 0.77 | CA5A (0.38) | CA5ACA5BGRM4KDM4EBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111019339-B | Spraying-free metallic polyamide material and preparation method and application thereof | 上海中镭新材料科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-1910287-B1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE PERINDOPRIL | LEK PHARMACEUTICALS (SI) | 2012-03-14 | — | — | EP | disclosed |
| US-7923570-B2 | Process for the preparation of crystalline perindopril | LEK PHARMACEUTICALS, D.D. (SL) | 2011-04-12 | — | — | US | disclosed |
| US-20080306135-A1 | Process for the Preparation of Crystalline Perindopril | LEK PHARMACEUTICALS D.D. (SI) | 2008-12-11 | — | — | US | disclosed |
| EP-1910287-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE PERINDOPRIL | LEK Pharmaceuticals D.D. (SI) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007017087-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE PERINDOPRIL | LEK PHARMACEUTICALS D.D. (SI) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306135-A1 | Process for the Preparation of Crystalline Perindopril | ACE, AGT, REN | CA5A 1978/4885CA5B 2329/4885GRM4 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.